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Synergy of Bosutinib and Chk-1 Inhibitor (PF) in Chemotherapy
Akhil Kolluri, Mentors: Dr. Steven Grant and Dr. Tri Nguyen
Virginia Commonwealth University
Chronic myelogenous leukemia (CML) is a form of cancer. This
disease affects the bone marrow cells that develop into the cells
of the blood (Chen, 2014). CML is caused by a deleterious
protein encoded by the chromosome called the Philadelphia
(Ph) chromosome (Chen, 2014). Current treatments for CML
include imatinib, the trade name for which is Gleevec, and bone
marrow transplants (Chen, 2014).
CML can be studied in clinical research using various cell lines.
BA/F3 is a model cell line that is commonly used to study CML
(Warmuth et al., 2007). This is because BA/F3 cells work well in
studying the signaling of kinases in the cell cycle, and how those
kinases can be inhibited by drugs like imatinib (Warmuth et al.,
2007). Cell lines that have been mutated are also very useful in
researching and modeling cancer cells in the body. According to
Watanabe et al. (2012), the T315I mutation is generally found in
cancer cells from patients who have relapsed after a period of
remission. The T315I mutation has been shown to cause
resistance to tyrosine kinase inhibitors like imatinib, one of the
most common treatments to CML (Watanabe et al., 2012).
Bosutinib is a newly tested kinase inhibitor that also functions in
cell signaling pathways important in the cell cycle of CML cells
(Boschelli et al., 2010). The chemical structure of bosutinib is
shown in Figure 1. Bosutinib blocks the phosphorylation of key
proteins like Bcr-Abl and CrkL in these cells that allow them to
proliferate (Boschelli et al., 2010). It has been shown that
bosutinib is effective in slowing the growth of CML cells
(Boschelli et al., 2010).
Chk-1 is a protein that has a function in regulating the many
checkpoints in the cell cycle (Zhang et al., 2009). PF-00477736
(PF) inhibits the Chk-1 protein, and has been shown to enhance
the effect of chemotherapy drugs like docetaxel (Zhang et al.,
2009).
Introduction
Figure 1. The chemical structure of bosutinib.
From Boschelli et al. (2010).
The purpose of this research was to find out if bosutinib can be
combined with a Chk-1 inhibitor (PF) to increase the efficacy of
the treatment. Two cell lines from CML were used in this
experiment: BAF3/T315I and Adult/T315I. Both of these cell
lines are resistant to imatinib due to the T315I mutation.
Cultures of these cells were incubated and maintained at 37° C.
These cell lines were also xenotransplanted into mice, and then
the xenograft tumors were extracted. Western blot analysis was
performed on the extracted tumor cells to determine protein
expression levels.
The cells were allowed to grow in RPMI medium with 10% fetal
bovine serum. The cell cultures were cut every Monday,
Wednesday, and Friday as cell density increased. The tumors
and the lysed proteins were stored in -80 ° C.
The cultured cells were treated with both bosutinib at 0.3 – 0.4
μM and PF at 1 – 1.2 μM individually as well as simultaneously.
The cell death was examined in each of these conditions over a
72-hour period. I would like to thank Dr. Steven Grant for providing me the
opportunity to work in his lab in the VCU Massey Cancer Center
and help conduct this research. I would also like to thank Dr. Tri
Nguyen for mentoring me in this research.
Methods
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Individual treatment of BAF3/T315I and Adult/T315I cell cultures
with bosutinib or with PF produced little cell death (less than
25%). However, the combined treatment of bosutinib and PF
showed a remarkable increase in cell death (around 65 – 75%).
These results are shown in Figure 2.
This chemotherapy combination was also tested on cells from
three CML patients. In these cells as well, individual treatments
of bosutinib and PF were ineffective, while the combined
treatment increased cell death. Also, normal CD34+ cells were
not as effected by the treatment as cancerous cells, only
showing around 20% lethality compared to around 50% for
cancerous cells.
Results also showed that the simultaneous treatment of
bosutinib and PF caused an increase in the expression of the
pro-apoptotic protein Bim and a decrease in the expression of
pro-survival protein Mcl-1.
Results
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Figure 2. The results of individual and simultaneous treatment of 
bosutinib and PF, showing apoptosis percentage at the end (left) and 
throughout (right) the 72-hour period.
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